A Phase I Open-label Multicentre Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

Trial Profile

A Phase I Open-label Multicentre Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs ALM 201 (Primary)
  • Indications Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Almac Discovery
  • Most Recent Events

    • 02 Feb 2018 Status changed to discontinued.
    • 12 Sep 2017 Interim results (n=8) presented at the 42nd European Society for Medical Oncology Congress
    • 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top